Home Featured Page 144

Featured

Latest

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley...

New 3D Structures of Cannabinoid Receptor Inform Safer Drug Design

PT344 – Susan Beaulieu – Epigenetics, Resilience, and Remembering

MindMed Board of Directors Approves Reverse Share Split

COMPASS Pathways plc announces second quarter 2022 financial results and business...

MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Canadian Patent Grant Strengthens Small Pharma’s International Position

Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough...

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health...

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

1...143144145...291 Page 144 of 291

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley...

New 3D Structures of Cannabinoid Receptor Inform Safer Drug Design

PT344 – Susan Beaulieu – Epigenetics, Resilience, and Remembering

MindMed Board of Directors Approves Reverse Share Split

COMPASS Pathways plc announces second quarter 2022 financial results and business...

MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Canadian Patent Grant Strengthens Small Pharma’s International Position

Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough...

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health...

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

EDITOR PICKS

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY